New drug showdown: can nipocalimab beat efgartigimod for muscle weakness?

NCT ID NCT07217587

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 27 times

Summary

This study tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive either drug, and some may switch from efgartigimod to nipocalimab. The goal is to see which drug better controls symptoms and improves daily activities.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Atrium Health Wake Forest Baptist
RECRUITING

Winston-Salem, North Carolina, 27157, United States
HSHS St. Elizabeth's Hospital
RECRUITING

O'Fallon, Illinois, 62269, United States
Henry Ford Hospital
RECRUITING

Detroit, Michigan, 48202, United States
Rambam Medical Center
RECRUITING

Haifa, 3109601, Israel
SFM Clinical Research LLC
RECRUITING

Boca Raton, Florida, 33487, United States
Sourasky Medical Center
RECRUITING

Tel Aviv, 6423906, Israel
Texas Neurology
RECRUITING

Dallas, Texas, 75206, United States
University of Connecticut
RECRUITING

Farmington, Connecticut, 06030, United States

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS